ArticleCureus2022
Clinical and Economic Impact of Rapid Blood Pathogen Identification Via Verigene.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBloodstream infections (BSIs) are associated with increased morbidity and mortality if not treated appropriately. Rapid identification of microorganisms will allow clinicians the opportunity to modify initial broad-spectrum antibiotic therapy and improve patient outcomes in bacteremia. We aim to evaluate the impact of the Verigene Gram-positive blood culture (BC-GP) technology on time to modification of antibiotic therapy by clinicians.
methodsThis was a retrospective research study conducted at Corpus Christi Medical Center. Verigene BC-GP technology was employed to rapidly identify microorganisms in patients with suspected Gram-positive bacteremia. Empiric antibiotic therapy was modified via de-escalation or escalation when culture results became available. The primary outcome for this study was the mean time to modification of antibiotic therapy after Verigene BC-GP results became available. Data analysis was conducted from data collected between January 2015 and August 2017 to assess the clinical and pharmacoeconomic impact of BC-GP.
resultsData were collected on 159 patients, with 123 of 159 (77%) meeting the inclusion criteria. The mean age was 66 ± 14.9 years, with 53/123 (43%) females and 70/123 (57%) males. Positive cultures identified were as follows:
conclusionThere is a significant time advantage to pathogen identification, therapy modification as well as a pharmacoeconomic benefit associated with the Verigene GC-GP system as compared to the conventional approach, which translates to positive patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.